Enable Innovative Drug Discover with DEL, FBDD and SBDD
Abstract:
DEL selections are binding assays conducted with mixtures of chemically diverse DNA-tagged ligands and a screening target. DEL selections use DNA sequence counts to measure target binding, where ideally higher affinity ligands will have higher counts than weaker affinity ligands. However, there is not always a clear relationship between DNA sequence count (assay signal) and binding affinity. This disconnect may be due to the fidelity of library chemistry, where reactions often do not go to completion, and also to repetitive rounds of binding and elution that are standard practice in most DEL selection experiments. We describe here a strategy that addresses both of these issues and provides a means to calculate ligand affinity from primary selection data. The reaction yields of selected compounds during DEL library synthesis can also be predicted with this method.
Res Commun. 2020 Dec 3;533(2):249-255
10.1016/j.bbrc.2020.04.029
Link:https://pubmed.ncbi.nlm.nih.gov/32444139/
HitGen Inc.
Building C2, NO.8, Huigu 1st East Road
Tianfu International Bio-Town,
Shuangliu District, Chengdu City,
Sichuan Province,P.R. China
Tel : +86-28-8519-7385
HitGen Pharmaceuticals Inc.(US Subsidiary)
Tel : +1-(508)-840-9646
Vernalis (R&D) Limited (UK Subsidiary)
Granta Park,Great Abington
Cambridge,CB21 6GB
United Kingdom
Tel : +44(0)1223-895555
We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for
More information